

Index

A

- Abciximab, 179–181
- Acanthosis nigricans, 55, 173
- Acebutolol, 112, 114, 115, 117
- Acecaïnide, 99–101
- ACEIs. *See* Angiotensin converting enzyme inhibitors (ACEIs)
- Acenocoumarol, 195–197, 200, 201
- Acetazolamide, 45, 55, 56, 143–145, 147, 148, 150, 151, 239
- Acetylsalicylic acid, 7, 47, 179–184, 242
- Acipimox, 165, 173
- Acneiform, 3, 26–27, 54, 100, 103, 117
- Acral cutaneous vesiculobullous and pustular eruption, 171
- Acrocyanosis, 159
- Acromelanosus, 102
- Acute generalized exanthematous pustulosis (AGEP), 9, 25–26, 48–50, 53, 55–57, 100, 101, 103, 130, 133, 145, 148, 171, 180, 184, 196, 202, 208, 210, 219, 231, 237–239, 242
- Adenosine, 95, 112, 123, 207, 210
- Adrenergic neuron blocker, 43, 56
- AGEP. *See* Acute generalized exanthematous pustulosis (AGEP)
- Airborne contact dermatitis, 117, 168, 240
- Alacepril, 67
- Allergic granulomatous angiitis, 105
- Alopecia, 3, 41, 45, 54, 55, 68, 71, 77, 90, 96, 105, 112, 116, 126, 138, 144, 158, 166, 167, 171, 172, 196, 200, 208, 210
- Alpha adrenergic receptor blockers, 45, 57, 207–208
- Alpha-2 adrenergic receptor agonist, 45, 54, 57, 93–96, 237
- Alteplase, 189–191
- Amiloride, 143–145, 149, 150, 239
- Aminocaproic acid, 5, 56, 207, 211, 243
- Amiodarone, 28, 34, 54, 56, 57, 123–126, 238
- Amlodipine, 40, 55, 57, 129–138, 238
- Amrinone, 157, 162
- ANA. *See* Antinuclear antibody (ANA)
- Anaphylactoid, 7, 46, 50, 55, 104, 114, 117, 162, 170, 172, 179, 180, 190, 198, 211
- Anaphylaxis, 7, 50, 114, 172, 179, 209, 230
- ANCA. *See* Antineutrophil cytoplasmic autoantibody (ANCA)
- Angioedema, 3, 7–9, 46, 49, 52, 54, 55, 67–70, 85–86, 96, 100, 104, 112, 114, 124–126, 130, 137, 143, 145, 150, 162, 166, 170, 172, 174, 179–180, 189, 190, 196, 198, 208, 210
- Angiotensin converting enzyme inhibitors (ACEIs), 5, 7, 16, 24, 28, 34, 40, 42, 44, 45, 47, 56, 57, 67–78, 85, 87, 114, 151, 236, 237
- Angiotensin II receptor blocker, 5, 54, 57, 85–90, 151, 237
- Angry back, 229
- Anisoylated plasminogen streptokinase activator complex, 189
- Anistreplase, 189–191
- Antianginal drug, 207, 211
- Antiarrhythmic, 5, 17, 36, 45, 54, 56, 57, 99–106, 111–117, 123–126, 129, 207, 210, 237, 238
- Anticardiolipin antibody, 159

- Anticoagulants, 13, 31, 40, 45, 46, 55–57, 99, 195–202, 241–242
 Anti-dsDNA, 114, 159, 167
 Antifibrinolytic, 211, 243
 Antihistone antibody, 41, 74, 93, 114, 134, 167, 182
 Antimyeloperoxidase antibody, 170
 Antineutrophil cytoplasmic autoantibody (ANCA), 34, 57, 88, 158, 159
 Antinuclear antibody (ANA), 41, 74, 93, 113, 134, 146, 158, 159, 167, 207
 Antiphospholipid antibody, 159, 196
 Aphthous, 16, 45, 90, 112, 117, 161
 Apixaban, 195
 Arachidonic acid, 180
 Aranidipine, 129
 Ardeparin, 195
 Argatroban, 195
 Arthus reaction, 200
 Arylamine, 57, 143, 229, 240
 Aspirin, 24, 31, 44, 55, 179–181, 183–185, 242
 Atenolol, 68, 73, 111–117, 238
 Atorvastatin, 165–167, 169–171
 Azelnidipine, 129
 Azilsartan, 85
 Azimilide, 123
- B**
- Baboon syndrome, 3, 9, 48, 202, 219, 225, 230, 231
 Barnidipine, 129
 Basophil activation test, 52
 Bemiparin, 195, 196, 199, 241
 Benazepril, 67, 68, 71, 75, 76, 236
 Bendroflumethiazide, 143, 145
 Benidipine, 129
 Benzophenone, 171, 172, 241
 Benzothiazepines, 129, 238
 Benzthiazide, 143
 Bepidil, 129
 Beta adrenergic receptor blockers, 111–117
 Beta blockers, 16, 17, 34, 40, 42, 43, 45, 46, 54, 56, 57, 78, 111–117, 123, 134, 237–238
 Betaxolol, 111, 112, 114
 Bezafibrate, 165, 172
 Bile acid resins, 173
 Bile acid sequestrants, 165
 Bisoprolol, 111, 112, 116, 238
 Bivalirudin, 195
 Black tongue, 96
 Bleeding, 38, 46, 55, 56, 162, 180–182, 195, 196
- Bosentan, 157–162, 240
 Bradykinin, 67–69, 85
 Bretylium, 123, 126
 Bullous, 3, 16, 20, 22–24, 36, 38, 45, 46, 51, 53–55, 68, 70–71, 86, 88–89, 113, 126, 130, 135–136, 145, 147–148, 160, 166, 170, 173, 185, 196, 199, 202, 210, 211
 Bullous hemorrhagic dermatosis, 55, 196, 199
 Bullous pemphigoid, 22–24, 68, 71, 86, 89, 130, 135, 136, 145, 147, 173, 185
 Bumetanide, 143, 145, 147, 148
 Burning mouth/tongue, 45, 77
- C**
- Calcinosis cutis, 55, 196, 200–201
 Calcium antagonists, 129
 Calcium channel blockers, 5, 13, 24, 28, 31, 34, 55, 57, 129–138, 238–239
 cAMP. *See* Cyclic adenosine monophosphate (cAMP)
 Candesartan, 85–90
 Cangrelor, 179
 Capillary fragility, 133, 138
 Captopril, 5, 24, 36, 44, 54, 56, 57, 67–78, 184, 220, 221, 236
 Carbonic anhydrase inhibitors, 45, 143, 149
 Cardioselective, 57, 111
 Carteolol, 111
 Carvedilol, 111, 112, 115–117, 168
 Cerivastatin, 165–167
 Certoparin, 195, 198, 200, 242
 Cheilitis, 105, 171
 Chloasma-like pigmentation, 151
 Chlorothiazide, 143–146, 149
 Chlorthalidone, 143, 145, 148–151
 Cholesterol embolism, 41, 55, 56, 189, 191
 Cholestyramine, 165, 173
 Cicatricial pemphigoid, 94, 95
 Cilazapril, 67, 68, 70, 74
 Cilnidipine, 129
 Cilostazol, 157, 162
 Ciprofibrate, 165
 Class I antiarrhythmics, 5, 17, 36, 45, 49, 54, 56, 57, 99–106, 237
 Class II antiarrhythmics, 57, 111–117
 Class III antiarrhythmics, 54, 57, 123–126, 238
 Clevidipine, 129
 Clofibrate, 165, 172
 Clonidine, 24, 42, 54, 56, 93–96
 Clopidogrel, 57, 179–185, 242
 Cold extremity, 115, 116, 151
 Colesevelam, 165

Colestipol, 165, 173
 Commercial product/drug, 197, 221, 222, 229, 230, 236–239, 241
 Compartment syndrome, 104
 Compound allergy, 89, 149, 230, 237, 239
 Connubial allergy, 230
 Contact dermatitis, 53, 55, 76, 95, 105, 111, 117, 126, 151, 158–161, 168, 197, 208, 211, 219, 225, 227, 232, 237, 241, 242
 Contact urticaria, 225, 230
 Control group, 220, 230, 232, 236
 COX-1. *See* Cyclooxygenase-1 (COX-1)
 Cross-photosensitization, 172, 241
 Cross reactions, 54, 57, 68, 78, 86, 90, 100, 117, 132, 143, 190, 196–198, 229, 236–243
 Cyclic adenosine monophosphate (cAMP), 95, 112
 Cyclooxygenase-1 (COX-1), 179
 Cyclopheniazide, 143

D

Dabigatran, 195, 196, 200–202
 Dalteparin, 57, 195, 196, 198–200, 202, 241
 Danaparoid, 57, 195–197, 199, 202, 241
 Delapril, 67
 Delayed type hypersensitivity, 47, 53, 143, 200, 202, 227, 234, 240–242
 Dermatomyositis, 55, 100, 166–167
 Dermographism, 170
 Desirudin, 195, 197
 Diagnostic tests
 in vitro, 52
 in vivo, 52
 Diaphoresis, 78, 90, 96, 208
 Diazoxide, 45, 55, 56, 157, 158
 Dichlorphenamide, 143
 DIF. *See* Direct immunofluorescence (DIF)
 Digital gangrene, 46, 56, 115, 159
 Digital ischemia, 159
 Digitalis glycosides, 123, 207, 210
 Digitoxin, 210
 Digoxin, 42, 105, 210
 Dihydropyridines, 129–131, 133, 238
 Diltiazem, 25, 30, 55–57, 129–138, 220, 236, 238
 Dimethyl sulphoxide (DMSO), 220, 227, 231
 Dipeptidyl peptidase IV inhibitors, 69
 Dipyrindamole, 179, 180, 184, 242
 Direct immunofluorescence (DIF), 22, 32, 51, 70, 147, 173, 211
 Direct thrombin inhibitors, 195
 Disopyramide, 99, 100, 104–106

Diuretics, 5, 16, 21, 24, 28, 31, 34, 36, 39, 41, 45, 55–57, 143–151, 220, 239–240
 DMSO. *See* Dimethyl sulphoxide (DMSO)
 Dobutamine, 208, 209
 Dofetilide, 123, 126
 Dopamine, 55, 208, 209
 Doxazosin, 207, 208
 DRESS. *See* Drug rash with eosinophilia and systemic symptoms (DRESS)
 Dronedarone, 123, 124, 126
 Drug hypersensitivity syndrome, 3, 40, 57, 75, 101–103, 129
 Drug intolerance, 230
 Drug rash with eosinophilia and systemic symptoms (DRESS), 3, 40, 48, 49, 53, 56, 57, 68, 77, 94, 96, 100–102, 117, 130, 137, 150, 158, 161, 162, 171, 172, 180, 183, 196, 201, 210, 229, 231, 236, 237, 240, 242, 243
 Dry skin, 126
 Dysgeusia, 45, 77, 90

E

Ecchymoses, 31, 41, 162, 182, 189–191, 195
 Eczematous, 3, 9–13, 22, 28, 29, 34, 46–48, 54, 55, 68, 75, 76, 86, 87, 94–95, 101, 130, 138, 144, 151, 166, 168, 169, 171, 184, 196–198, 202, 219, 227, 228, 231, 232, 236, 240, 241
 Edema, 7, 9, 17, 25, 28–30, 40, 43, 46, 55, 56, 68, 78, 90, 96, 103–105, 126, 130–131, 144, 157, 158, 160, 171–173, 208, 209, 212
 Edoxaban, 195
 Efonidipine, 129
 EMPACT, 22, 100, 102
 Enalapril, 24, 54, 56, 67–78, 236
 Encainide, 99, 106
 Enoxaparin, 55, 195–201, 241
 Enoximone, 157
 Eosinophilic fasciitis, 78, 166, 169
 Epicutaneous test, 75, 197
 Epinephrine, 55, 69, 114, 208, 209
 Eplerenone, 143
 Epoprostenol, 55, 56, 157–160, 162
 Eprosartan, 85–88, 90
 Eptifibatide, 179–181
 Erythema multiforme, 3, 21–22, 48, 56, 86, 89, 90, 100, 102, 105, 112, 116, 117, 130, 136, 145, 148–149, 160, 171, 172, 180, 183, 190
 Erythema nodosum, 3, 34, 45, 105, 138
 Erythroderma, 3, 4, 9, 15, 34–36, 40, 55, 56, 68, 76, 100, 102, 105, 129, 130, 136, 151, 158, 160, 184, 201, 207, 231, 238

Erythromelalgia, 130, 134–135
 Esmolol, 111
 Ethacrynic acid, 143
 Exanthema, 3–5, 7, 9, 13, 46, 48, 51, 86,
 90, 151, 173
 Exanthematous, 9, 25–26, 48, 55, 57, 75, 100,
 101, 103, 130, 132, 133, 145, 148, 171,
 180, 181, 184, 196, 198, 202, 208, 210,
 219, 241, 242
 Exfoliative dermatitis, 3, 4, 9, 15,
 34–36, 46, 56, 76, 136
 Extravasation, 31, 126, 202, 209
 Ezetimibe, 165, 170, 174

F

Facial edema, 40, 46, 78, 90, 103, 105,
 172, 208
 Factor Xa inhibitors, 195
 Felodipine, 129–131, 133, 134
 Fenofibrate, 56, 57, 165, 171, 172, 241
 Fenoldopam, 157
 Fibrate, 28, 55, 57, 165, 171–172, 241
 Fibric acid, 165
 Fibrinolytic, 189–191
 Fingernails, 210
 Fixed drug eruption, 3, 16–20, 56, 100, 103,
 112, 116, 137, 143, 151, 158, 162, 173,
 180, 183, 202, 209, 210, 219, 222,
 225, 227
 Flare-up reaction, 230
 Flecainide, 99, 100, 103–106
 Fludione, 56, 195–197, 201, 202, 242
 Flushing, 43, 55, 56, 106, 126, 130, 131, 157,
 158, 173, 191, 208–210
 Fluvastatin, 57, 165–167, 169–171
 Follicular mucinosis, 74, 78
 Fondaparinux, 57, 195, 197–199, 202, 241
 Fosinopril, 67, 68, 70, 75, 76,
 78, 236
 Fraxiparin, 195
 Furosemide, 16, 24, 44, 45, 56, 143, 145,
 147–151, 239

G

Gallopamil, 129
 Ganglionic blocker, 207, 209–210, 216
 Gangrene, 46, 55, 56, 115, 116, 159, 191,
 197, 208, 209
 Gemfibrozil, 42, 165, 172
 Genetic predisposition, 101, 131, 149
 Gingival hyperplasia, 3, 45, 54–56,
 100, 105, 130, 131, 137

Glossitis, 105
 Glossodynia, 77
 Glyceryl trinitrate, 55–57, 157, 158, 160
 Granuloma annulare, 106, 138
 Granulomatous, 44, 78, 96, 105, 138, 145,
 151, 166, 170, 202
 Grinspan's syndrome, 135
 Guanabenz, 93–96
 Guanadrel, 209
 Guanethidine, 209, 210
 Guanfacine, 93, 95, 96
 Gynecomastia, 55, 96, 130–132, 151, 210

H

Hair, 45, 94, 116, 138, 144, 157, 158, 173, 225
 Hematologic, 40, 181, 183
 Hematoma, 181, 190, 195
 Hemorrhage, 39, 181, 189
 Henoch Schönlein purpura (HSP), 32, 51,
 75, 88, 104
 Heparin, 13, 40, 53, 55–57, 195–202,
 235, 241
 Heparinoid, 57, 195, 198, 236, 241
 Hess testing, 138
 Hirsutism, 100, 105, 138
 Hirudin, 57, 195, 197, 198, 202, 241
 Histopathologic, 9, 16, 21, 25, 44, 46, 50,
 70, 72–75, 87–90, 94, 103, 105, 112,
 135, 146–148, 159, 160, 171, 173,
 197, 199, 211, 231, 236
 HITT syndrome, 196
 HMG-CoA reductase inhibitors. *See*
 3-hydroxy-3-methylglutaryl coenzyme
 A reductase inhibitor
 HSP. *See* Henoch Schönlein
 purpura (HSP)
 Hydralazine, 34, 41, 55, 56, 157–159, 162
 Hydrochlorothiazide, 13, 28–31, 73, 76, 86,
 87, 89, 90, 143–146, 148–151, 220,
 232, 234, 235, 237, 239
 Hydroflumethiazide, 143
 3-Hydroxy-3-methylglutaryl coenzyme
 A reductase inhibitor, 165
 Hyperhidrosis, 45, 90, 106, 117, 126, 138,
 162, 173, 191, 209, 210
 Hyperkeratosis, 113, 138
 Hyperpigmentation, 3, 16, 17, 19, 23, 28–32,
 54–56, 71, 95, 100, 102, 117, 124–125,
 130, 132, 133, 135, 147
 Hypersensitivity
 type 1, 7, 47, 52, 143, 219
 type 3, 7, 43, 47, 191
 type 4, 47, 48, 52, 113, 219, 241

Hypertrichosis, 3, 45, 55, 56, 145, 151,
157–158, 208
Hypohidrosis, 45

I

Ibutilide, 123, 126
Ichthyosis, 55, 57, 94, 166, 169, 172, 173
Idiosyncratic, 40, 46, 138
Idraparinux, 195, 196, 199
Imidapril, 67
Immediate type hypersensitivity, 219, 227, 230
Immunofluorescence microscopy, 51
Indapamide, 46, 56, 143, 145–151, 240
Indirect immunofluorescence (IIF), 70, 135,
136, 199
Injection site, 54, 55, 100, 104, 196–200,
202, 208, 209, 241
Interstitial granulomatous drug
 reaction, 44, 78, 138, 145, 151, 166, 170
Intolerance, 46, 47, 210, 230
Intradermal (intracutaneous) test, 50, 52, 75,
148, 150, 197, 199, 210, 230, 235,
239, 241
Iodinated agents, 125
Iodine, 42, 125, 126
Iododerma, 124, 126
Irbesartan, 85–90, 149, 237, 239
Ischemia, 104, 135, 159, 209
Isoproterenol, 208
Isosorbide dinitrate, 57, 157, 158, 160–162
Isosorbide mononitrate, 157, 162
Isradipine, 130, 131
Ivabradine, 207, 211, 212

K

Kaposi sarcoma, 68, 74
Kounis syndrome, 199

L

Labetalol, 111–115, 117
Lacidipine, 129, 131
Laropiprant, 173
La/SSB, 41, 134
Latency period, 23, 40, 50, 70, 76, 87, 113,
125, 134, 167, 182
Lepirudin, 195–200, 241
Lercanidipine, 129, 131
Leukocytoclastic vasculitis, 32, 33, 43, 47,
88, 104, 115, 126, 149, 159, 183, 190,
197, 200
Lichenoid, 3, 13–16, 28, 34, 45–48, 54–56,
68, 71, 72, 77, 86, 89, 94, 96, 101, 105,

112–114, 117, 130, 133, 135, 144, 145,
149, 158, 162, 166, 171, 180, 182, 208,
237, 239, 241

Lichen planus, 3, 13, 15, 23, 68, 71–72, 78,
89, 105, 112–114, 130, 135, 145, 158,
166, 170, 182
Lichen planus pemphigoides, 23, 68, 71,
166, 170
Lidocaine, 57, 99–101, 103–105
Linear IgA dermatosis, 22–24, 51, 68, 71, 86,
88, 100, 105, 126, 130, 136, 145,
147, 166, 170
Lipid lowering drug, 43, 45, 55, 57, 165–174,
179, 240–241
Lisinopril, 67–75, 77, 78, 87, 236
Livedo reticularis-like, 101
LMWHs. *See* Low molecular weight
 heparins (LMWHs)
Loop-active agents, 143
Losartan, 85–90, 146, 239
Lovastatin, 57, 165–167, 169–171
Low molecular weight heparins
 (LMWHs), 53, 55–57, 195–200, 202,
241
Lupus erythematosus, 3, 41–42, 51, 54–56,
68, 74, 93, 94, 99–101, 112–115, 124,
125, 130, 134, 145, 146, 158–159,
166–168, 180, 182, 207, 209
Lymphocyte activation/proliferation
 test, 238
Lymphocyte transformation test (LTT), 53, 75,
148, 161, 240
Lymphocytic vasculitis, 75, 236
Lymphomatoid, 3, 40, 54, 56, 68, 72, 86–88,
100, 103, 138, 151

M

Macrophage migration inhibition (MIF)
 test, 73
Maculopapular, 3–6, 30, 34, 38, 46–50,
53–56, 68, 75, 77, 86–90, 95, 100, 101,
103, 105, 130, 132, 138, 145, 150,
158–161, 172, 173, 180, 181, 184, 189,
191, 196, 199–201, 210–212, 219, 231,
238–240, 242, 243, also *See* Morbilliform
Malar rash, 41, 125
Manidipine, 129, 130
Mast cell degranulation (MCD) test,
 52, 73
Mecamylamine, 209, 210
Melanonychia, 138
Methyldopa, 16, 54, 56, 93–96, 237
Metolazone, 143, 145, 149
Metoprolol, 40, 111–117

Mexiletine, 40, 54, 56, 57, 99–101, 103–106, 237
 Mibefradil, 129, 130
 Midodrine, 208, 209
 MIF test. *See* Macrophage migration inhibition (MIF) test
 Milrinone, 157, 162
 Mineralocorticoid antagonists, 143
 Minimal erythema dose, 232
 Minoxidil, 45, 55, 56, 157–160, 162
 Moexipril, 67
 Monatepil, 129
 Morbilliform, 4, 49, 51, 219, 231, also *See* Maculopapular
 Moricizine, 99, 100, 104–106
 Moxonidine, 93, 94, 96
 Mucocutaneous ulcer, 55, 158, 161
 Mucosal, 3, 16, 20–22, 25, 36, 45, 77–78, 86, 89, 90, 96, 100, 102, 105, 113, 114, 117, 125, 132, 133, 137, 149, 150, 166, 182, 185, 208
 Mucosal ulcer, 105
 Multiple drug allergy (MDA), 49, 50, 229
 Mycosis fungoides, 34, 40, 72, 88–90, 103, 151

N

Nadolol, 111–113, 116, 117
 Nadroparin, 55, 195–197, 199–201, 241
 Nail, 3, 15, 28, 38, 46, 56, 86, 90, 113, 116–117
 discoloration, 162
 dystrophy, 138
 Naranjo adverse drug reaction probability scale, 51
 Nebivolol, 111–113
 Necrosis, 3, 24, 32, 36, 38, 40–41, 48, 55, 56, 104, 115, 126, 191, 196, 197, 208, 209
 Necrotizing vasculitis, 32, 75, 159
 Nesiritide, 157, 162
 Niacin, 55, 165, 173
 Nicardipine, 129–134, 137, 239
 Nicolau syndrome, 100, 104
 Nicorandil, 43, 55, 157, 158, 161
 Nicotinic acid, 161, 165, 173
 Nifedipine, 45, 55–57, 129–138, 238, 239
 Nikolsky's sign, 22, 38, 39
 Nilvadipine, 129
 Nimodipine, 129–132, 138, 238
 Nisoldipine, 129
 Nitradipine, 129
 Nitrate, 57, 157
 Nitrendipine, 129–132, 134

Nitroglycerin, 55, 56, 157–162
 Nitroprusside, 157, 162
 Nonsteroidal antiinflammatory drugs (NSAIDs), 3, 7, 17, 21, 24, 28, 34, 36, 39, 42, 52, 78, 114, 179, 220, 231
 Norepinephrine, 55, 208, 209

O

Oculomucocutaneous syndrome, 54, 112, 113
 Olmesartan, 85–87, 90
 Onycholysis, 46, 78
 Open test, 52, 114, 225, 227
 Oral anticoagulants, 195, 200, 201
 Oral lichenoid, 3, 15, 77, 96, 117
 Oral lichen planus, 78, 135
 Oral mucosal, 77–78, 86, 90, 96, 100, 105, 117, 132, 133, 137, 208
 Oral rechallenge, 125, 182, 184, 210, 239, 242
 Oral tolerance, 230
 Orogenital ulcer, 159
 Oxprenolol, 111–113, 115, 117

P

Palmar erythema, 126, 172, 173
 Palmar hyperkeratosis, 138
 Panniculitis, 34, 115, 201
 Para-amino group, 143, 144, 229
 Patch test, 50, 52, 75, 77, 89, 94, 102, 103, 117, 124, 132, 133, 136, 148–150, 161, 168, 181, 183, 184, 197, 198, 201, 202, 211, 219–232, 236–243
 Patch testing in loco, 116, 183, 225, 242
 Patch test reactions
 false negative, 220, 230, 242
 false positive, 229–230
 irritant, 220, 227, 236, 239
 positive, 75, 197, 201, 202, 220–222, 228–232, 236–242
 Pedal edema, 130, 131
 Pemphigoid, 3, 22–24, 51, 55, 56, 68, 71, 86, 89, 94, 95, 117, 130, 135–136, 145, 147, 166, 170, 173, 185
 Pemphigoid nodularis, 135, 136
 Pemphigus, 3, 20, 22–24, 51, 54–56, 68, 70, 86, 89, 130, 135–136, 145, 147
 Pemphigus foliaceus, 70, 86, 89, 135, 147
 Pemphigus vulgaris, 16, 20, 22, 23, 70, 135, 136, 145, 147
 Penbutolol, 111
 Pentaerythritol tetranitrate, 55, 56, 157, 158, 160

- Pentasaccharides, 195, 241
 Pentosan polysulfate, 195, 198,
 202, 241
 Pentoxifylline, 207, 210–211
 Perindopril, 67, 68, 73
 Peripheral edema, 43, 55, 56, 78, 90, 96,
 130–131, 208, 209, 212
 Peripheral vascular disease, 54, 112,
 115–116
 Pentaerythritol tetranitrate, 55, 56, 157
 Periungual pigmentation, 138
 Petechial, 32, 100, 144
 Peyronie's disease, 54, 112, 115
 Phenindione, 195, 196, 201, 202
 Phenoxybenzamine, 207
 Phentolamine, 207, 208
 Phenylalkylamines, 129, 238
 Phenylephrine, 208, 209, 242
 Phenytoin, 22, 30, 36, 39, 40, 45, 54, 56, 57,
 99–105, 229, 231
 Phlebitis, 104, 208, 209
 Phosphodiesterase inhibitors, 157
 Photoallergy, 28, 52, 133, 145, 146, 219,
 232, 233, 235–237, 239
 Photochallenge, 146, 171, 172, 239, 241
 Photodistributed, 30, 74, 101, 146, 149,
 166, 167
 Photoexposed, 74, 132, 133, 182
 Photometabolite, 230
 Photo-onycholysis, 28, 46, 56, 146
 Photopatch test, 52, 74, 101, 133, 145, 146,
 169, 171, 172, 219, 230, 232–241
 Phot scratch test, 133, 172, 235, 239, 241
 Photosensitivity, 3, 15, 16, 28–31, 41, 52,
 54–56, 68, 74, 90, 93, 94, 100, 101,
 117, 123–124, 130, 132, 133, 144–146,
 166, 169, 171, 172, 232, 237–241
 Phototest, 52, 145, 169, 233, 235, 240
 Phototoxic, 28, 52, 123, 133, 145, 232, 233
 P-i concept, 9, 48–49
 Pigmentation, 17, 30, 78, 90, 102, 105,
 123–125, 138, 144, 151, 202
 Piloerection, 209
 Pincer nail, 56, 112, 117
 Pindolol, 111–115
 Pitavastatin, 165
 Pityriasis rosea-like, 44, 68, 71, 73, 151
 Platelet glycoprotein IIb/IIIa receptor
 antagonists, 179
 Platelet inhibitors, 5, 16, 17, 31, 55–57,
 179–185, 242
 Polysensitivity, 229
 Porphyria, 3, 23, 105, 147, 171
 Porphyria cutanea tarda, 23, 147, 171
 Practolol, 54, 111–115, 117
 Pranidipine, 129
 Prasugrel, 57, 179–181, 242
 Pravastatin, 165–171, 240
 Prazosin, 207
 Prick test, 50, 52, 148, 150, 180, 199, 209,
 210, 230, 235, 239
 Procainamide, 41, 54, 56, 99–101, 104, 106
 Propafenone, 99, 100, 103–106
 Propranolol, 111–117, 238
 Propylene glycol, 160, 229
 Prostaglandin, 173, 179, 180
 Protamine sulfate, 207, 211
 Pruritus, 4, 34, 43, 57, 77, 90, 95, 104, 117,
 126, 137, 150, 162, 170, 172, 173, 184,
 191, 198, 202, 208–210
 Pseudoallergic, 46, 179, 230
 Pseudolymphoma, 3, 40, 87–89, 103, 117, 138
 Pseudoporphyria, 22–24, 56, 105, 126,
 145, 147–148
 Psoriasiform, 41–43, 54, 55, 68, 72–73, 76,
 86, 94, 95, 105, 111–113, 116, 130,
 134, 151, 171, 185, 210
 Psoriasis, 3, 34, 42, 57, 68, 72–73, 86–87, 89,
 94, 95, 105, 111–112, 117, 126, 130,
 134, 151, 171, 172, 184, 210
 Purple glove syndrome, 100, 104
 Purple toe, 55, 196, 201
 Purpura, 3, 31–33, 43, 54, 55, 57, 75, 88, 96,
 100, 104, 105, 115, 117, 130, 133, 137,
 138, 151, 159, 162, 180–182, 189–191,
 195, 196, 200, 208, 210
 Purpuric, 4, 31–33, 47, 137, 159, 171, 172,
 189, 191, 195, 211
 Pustular, 3, 25–26, 46–48, 54, 72, 73, 101,
 103, 112, 151, 171, 184, 202, 231
 Pyoderma gangrenosum-like ulcer, 159
- Q**
 Quinapril, 67, 68, 70, 74–76, 236
 Quinidine, 26, 28, 30, 31, 34, 54, 56,
 99–106, 237
- R**
 Radiation recall dermatitis, 171
 Radiation therapy, 22, 100, 102, 146
 Ramipril, 67, 68, 70–77, 236
 Ranolazine, 207, 211, 212
 Raynaud's phenomenon, 115
 Reserpine, 43, 56, 209
 Reteplase, 189, 190
 Rheumatoid factor, 113
 Rilmenidine, 93, 94, 96
 Rivaroxaban, 195

Rosacea, 162
 Ro/SSA, 41, 74, 115, 134, 167, 170, 174
 Rosuvastatin, 165–167, 170, 171

S

Scalded mouth syndrome, 45, 54, 68, 77, 78
 Scalp pruritus, 209
 Scalp tingling, 117
 SCLE. *See* Subacute cutaneous lupus erythematosus (SCLE)
 Scleroderma, 78, 100
 Scratch-patch test, 235
 Scratch test, 50, 52, 170, 235
 SDRIFE. *See* Symmetrical drug related intertriginous and flexural exanthema (SDRIFE)
 Serial dilution, 220, 221, 230, 232, 236, 237
 Serum sickness-like reaction, 3, 34, 43, 55, 180, 184, 189–191, 211
 SH. *See* Sulfhydryl (SH)
 Sildenafil citrate, 157
 Simvastatin, 117, 165–171, 174, 240
 Sjögren-like syndrome, 100
 Skin thickening, 138
 Skin ulcer, 45, 171
 SLE. *See* Systemic lupus erythematosus (SLE)
 Sneddon–Wilkinson disease, 106
 Sodium channel blockers (inhibitors), 57, 99, 143
 Sodium lauryl sulfate, 229, 236, 239
 Sotalol, 111–113, 115, 123
 Spiny keratoderma, 171
 Spirapril, 67
 Spironolactone, 24, 56, 143–151, 229, 236, 239
 Statin, 165–170
 Stevens–Johnson syndrome, 3, 36–37, 48, 55, 57, 68, 76, 86, 90, 100, 102, 112, 116, 117, 129, 130, 136, 145, 148–149, 158, 160, 172, 183
 Stomatitis, 16, 102, 105
 Stomatodynia, 77
 Streptokinase, 55, 113, 189–191
 Subacute cutaneous lupus erythematosus (SCLE), 3, 41, 42, 74, 100, 115, 130, 134, 145, 146, 166–168, 182
 Subcutaneous provocation, 53, 197, 198, 200, 202, 241
 Sulfonamide diuretics, 57, 143, 239, 240
 Sun-exposed, 15, 16, 23, 28–30, 86, 101, 102, 123–125, 133, 134, 144, 146, 147, 159
 Sweet syndrome, 44, 145, 150, 159
 Symmetrical drug related intertriginous and flexural exanthema (SDRIFE), 3, 9, 13, 48, 86, 219, 225, 231

Sympathomimetics, 40, 55, 56, 207–209, 242
 Systemic challenge, 50, 53
 Systemic lupus erythematosus (SLE), 3, 41, 74, 93, 94, 99, 100, 104, 113, 114, 125, 145, 146, 158, 159, 166–168, 182, 207

T

Tape-stripping, 220, 230, 241
 Taste disturbance, 45, 77
 Telangiectasia, 34, 55, 130, 132, 133, 159
 Telmisartan, 13, 85, 86, 89, 90, 151
 Tenecteplase, 189
 Terazosin, 207, 208
 Tetraols, 129
 Thiazide, 13, 24, 28, 41, 44, 55, 57, 143–145, 149, 239, 240
 Thiazide-like diuretics, 143
 Thiazide-type diuretics, 143
 Thienopyridine derivatives, 179, 181
 Thiol, 24, 67, 70
 Thrombin inhibitors, 195
 Thrombocytopenia, 31, 47, 104, 181, 182, 195–197
 Thrombocytopenic purpura, 55, 180–182, 210
 Thrombolytic, 31, 34, 41, 55, 56, 189–191
 Thrombosis, 99, 196, 197, 199, 241
 Ticagrelor, 179
 Ticlopidine, 55–57, 179–185, 242
 Tilisolol, 117, 238
 Timolol, 111–113
 Tinzaparin, 195, 196, 199, 200
 Tirofiban, 179–181
 Tissue plasminogen activator, 189
 Tocainide, 57, 99–102, 104–106
 Torsemide, 143, 144
 Toxic epidermal necrolysis, 3, 38–39, 48, 55, 57, 68, 76, 100, 102, 105, 112, 116, 124, 125, 129, 130, 136, 148–149, 158, 160, 171, 180, 183, 202
 Trandolapril, 67
 Transdermal, 54, 55, 95, 158–161
 Triamterene, 143–146, 148, 239
 Trichlormethiazide, 143, 149
 Trimetazidine, 207, 211

U

Ulcer, 41, 55, 90, 112, 117, 159, 161, 171, 172
 Ultraviolet (UV), 28, 219, 230, 232–234
 Unfractionated heparin, 197, 241
 Urokinase, 189, 190

- Urticaria/urticarial, 3, 7–9, 22, 32–34, 43, 47, 50, 52, 54–56, 67–70, 85–86, 96, 100, 104, 112, 114, 117, 124, 125, 130, 137, 143, 145, 150, 159, 160, 162, 166, 170, 172–174, 179–182, 184, 189–191, 196, 198–199, 208–210, 225, 230
- Urticarial vasculitis, 32–34, 43, 104, 170
- UV. *See* Ultraviolet (UV)
- UVA, 28, 52, 101, 123, 133, 145, 146, 171, 232–235, 237–239, 241
- UVB, 52, 123, 133, 145, 172, 232–235, 238, 239, 241
- V**
- Valsartan, 72, 78, 85–87, 89, 90
- Vasculitis, 3, 32–34, 43, 47, 51, 54, 55, 57, 68, 75, 86, 88, 100, 104, 112, 115, 124, 126, 137, 145, 149, 158, 159, 166, 170, 171, 180, 183, 184, 189–191, 196, 197, 199, 200, 209, 210, 236
- Vasodilatory, 36, 43, 55–57, 131, 133, 157–162, 173, 240
- Verapamil, 57, 129–132, 134–138, 238
- Vesiculobullous, 23, 24, 171
- W**
- Warfarin, 40, 46, 55, 56, 195–197, 199–201
- Wickham striae, 13, 14, 135
- X**
- Xanthinol nicotinate, 165, 173
- Xerophthalmia/dry eye, 113
- Xerosis, 43, 55, 57, 90, 106, 151, 162, 166, 168, 169, 172, 173, 208
- Xerostomia, 45, 54, 57, 77, 90, 93, 94, 96, 100, 105, 112, 117, 137, 151, 162, 208–210, 212
- Z**
- Zofenopril, 67